A Phase II Study of Temsirolimus (Torisel) and Erlotinib (Tarceva) in Platinum-Refractory or -Ineligible, Advanced, Squamous Cell Carcinoma of the Head and Neck
Phase of Trial: Phase II
Latest Information Update: 12 Aug 2015
At a glance
- Drugs Erlotinib (Primary) ; Temsirolimus (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 01 Dec 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 18 Sep 2012 Planned End Date changed from 1 Nov 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov record.
- 29 Dec 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.